Risks associated with hypoglycemic pharmacotherapy in elderly patients with neurological and psychiatric disorders

Capa


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Type 2 diabetes mellitus is characterized by its high prevalence among the elderly and senile populations. It is estimated that approximately one in five individuals aged 65 or more live with diagnosed or undiagnosed type 2 diabetes mellitus. These estimates support the reasonable hypothesis that the disease is associated with advanced age. Of particular relevance is the observation that type 2 diabetes mellitus in geriatric practice often co-occurs with neurological and psychiatric disorders.

A comprehensive analysis of the scientific studies published over the past 5 years by Russian and international authors offers a detailed description and discussion of the potential risks associated with hypoglycemic pharmacotherapy for type 2 diabetes mellitus in elderly and senile patients with neurological and psychiatric disorders. This study provides an overview of the pharmacodynamic characteristics of the main classes of hypoglycemic agents, thereby facilitating an assessment of their safety in geriatric populations. The following discussion addresses the requirements and principles of hypoglycemic pharmacotherapy in elderly patients, with the aim of reducing the risks of adverse reactions. Metformin has been identified as the hypoglycemic agent with the lowest risk of adverse reactions for elderly and senile patients with impaired central nervous system function who are treated for type 2 diabetes mellitus. Novel groups of antidiabetic medications, such as incretin mimetics and gliflozines, have emerged as promising candidates for treatment. Sulfonylureas, glitazones, and glinides are not recommended for elderly individuals.

Texto integral

Acesso é fechado

Sobre autores

Vasiliy Novikov

Smolensk State Medical University

Autor responsável pela correspondência
Email: novikov.farm@yandex.ru
ORCID ID: 0000-0002-0953-7993
Código SPIN: 1685-1028

MD, Dr. Sci. (Medicine)

Rússia, 28, Krupskaya st., Smolensk, 214019

Ksenia Zagnet

Smolensk State Medical University

Email: zagnet@smolgmu.ru
ORCID ID: 0000-0003-0761-7129
Código SPIN: 9179-0791

Assistant Lecturer

Rússia, 28, Krupskaya st., Smolensk, 214019

Elena Pozhilova

Smolensk State Medical University

Email: farmfpk@smolgmu.ru
ORCID ID: 0000-0002-7372-7329
Código SPIN: 6371-6930

MD, Cand. Sci. (Medicine), Assistant Professor

Rússia, 28, Krupskaya st., Smolensk, 214019

Bibliografia

  1. Tkacheva ON, Ostroumova OD, Kotovskaya YV, et al. Deprescribing of glucose-lowering medications in the elderly. Clinical Pharmacology Therapy. 2019;28(3):62–67. doi: 10.32756/0869-5490-2019-3-62-67 EDN: ESMXQA
  2. Akhundova KhR, Dudinskaya EN, Tkacheva ON. Geriatric aspects of diabetes mellitus. Russian Journal of Geriatric Medicine. 2020;(3):250–259. doi: 10.37586/2686-8636-3-2020-250-259 EDN: BOITSU
  3. Gadó K, Tabák GÁ, Vingender I, et al. Treatment of type 2 diabetes mellitus in the elderly - Special considerations. Physiol Int. 2024;111(2):143–164. doi: 10.1556/2060.2024.00317 EDN: NSROXL
  4. Glinkina IV, Balashova AV, Shyman AS, et al. Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus. Medical Council. 2021;(7):56–67. doi: 10.21518/2079-701X-2021-7-56-67 EDN: KPXUDT
  5. Zyryanov SK, Butranova OI. Glucose-lowering drugs in geriatrics. Moscow: GEOTAR-Media; 2024. 208 p. (In Russ.) doi: 10.33029/9704-8163-9-HAG-2024-1-208 EDN: CNBVBD
  6. Novikov VE. Possibilities of pharmacological neuroprotection in cerebrovascular insufficiency. Moscow: RITM; 2024. 148 p. (In Russ.)
  7. Novikov VE, Levchenkova OS. Perspectives of use of inducers of the hypoxia adaptation factor in therapy of ischemic diseases. Journal of Ural Medical Academic Science. 2014;(5):132–138. EDN: TKZNBL
  8. Novikov VE, Levchenkova OS. Erythropoietin and vascular endothelial growth factor level in normoxia and in cerebral ischemia under pharmacological and hypoxic preconditioning. Biomedical Chemistry. 2020;66(4):339–344. doi: 10.18097/PBMC20206604339 EDN: XDXCGU
  9. Novikov VE, Levchenkova OS, Pozhilova EV. Mitochondrial nitric oxide synthase in mechanisms of cell adaptation and its pharmacological regulation. Vestnik of the Smolensk State Medical Academy. 2016;15(1):14–22. EDN: VVVMDB
  10. Novikov VE, Levchenkova OS, Pozhilova EV. Mitochondrial nitric oxide synthase and its role in the mechanisms of cell adaptation to hypoxia. Reviews on Clinical Pharmacology and Drug Therapy. 2016;14(2):38–46. doi: 10.17816/RCF14238-46 EDN: WFETDV
  11. Novikov VE, Pozhilova EV. Pharmacological neuroprotection in cerebrovascular insufficiency: possible approaches. Psychopharmacology and Biological Narcology. 2024;15(1):23–32. doi: 10.17816/phbn626125 EDN: ZZEGEE
  12. Novikov VE. Pharmacological neuroprotection in ischemic brain lesions (part 1. physiological and pathogenetic targets for pharmacological neuroprotection). Vestnik of the Smolensk State Medical Academy. 2024;23(1):35–47. doi: 10.37903/vsgma.2024.1.5 EDN: GSQPVA
  13. Novikov VE, Pozhilova EV. Pharmacological neuroprotection in ischemic brain lesions (part 2. possible approaches to pharmacological neuroprotection). Vestnik of the Smolensk State Medical Academy. 2024;23(2):54–64. doi: 10.37903/vsgma.2024.2.6 EDN: CLCRVT
  14. Novikov VE, Pozhilova EV. Pharmacological neuroprotection in ischemic brain lesions (part 3. justification of the choice and pharmacodynamics of drugs for blockade of ischemic cascades). Vestnik of the Smolensk State Medical Academy. 2024;23(3):47–60. doi: 10.37903/vsgma.2024.3.6 EDN: DZGXGB
  15. Novikov VE, Levchenkova OS, Ivantsova EN, et al. Mitochondrial dysfunctions and antihypoxants. Reviews on Clinical Pharmacology and Drug Therapy. 2019;17(4):31–42. doi: 10.7816/RCF17431-42 EDN: SHCYZM
  16. Verbovoy AF, Verbovaya NI, Dolgikh YA. Fixed combinations of glucose-lowering drugs in type 2 diabetes treatment. Medical Council. 2022;16(23):199–204. doi: 10.21518/2079-701X-2022-16-23-199-204 EDN: INPBCB
  17. Khokhlov AL, Gorelov KV, Rybachkova YV. To the assessment of the use of sugar-reducing drugs from the position of safety. Patient-Oriented Medicine and Pharmacy. 2023;1(1):41–48. doi: 10.37489/2949-1924-0006 EDN: KSUVVY
  18. Bulgakova SV, Dolgikh YA, Sharonova LA, et al. Problems of choosing hypoglycemic therapy in elderly patients (literature review). Advances in Gerontology. 2023;36(1):115–125. doi: 10.34922/AE.2023.36.1.015 EDN: KLBGBG
  19. Pereverzev AP, Ostroumova OD, Tkachev ON. Potential drug interactions of oral hypoglycemic drugs that increase the risk of hypoglycemia. Pharmateca. 2019;26(4):96–99. doi: 10.18565/pharmateca.2019.4.96-99 EDN: DOJRMD
  20. Chernikova NA, Knyshenko OA. Current management of type 2 diabetes mellitus: what to pay attention to in outpatient settings. Doctor. Ru. 2021;20(2):40–44. doi: 10.31550/1727-2378-2021-20-2-40-44 EDN: DVNVUG
  21. Misnikova IV, Kovaleva YA, Gubkina VA, et al. Gliclazide mr in the structure of antihyperglycemic therapy according to the data of Moscow region diabetes register. Diabetes Mellitus. 2022;25(2):166–173. doi: 10.14341/DM12799 EDN: TTJSUN
  22. Seaquist ER, Phillips LS, Ghosh A, et al. Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes. PLoS One. 2024;19(11):e0309907. doi: 10.1371/journal.pone.0309907 EDN: VIHJFL
  23. Mohamed AJ, AlSaffar AH, Mohamed AA, et al. Effect of GLP-1 receptor agonists on renal functions and diabetic nephropathy. Cureus. 2024;16(10):e71739. doi: 10.7759/cureus.71739 EDN: NUZDOA
  24. Lisco G, Bartolomeo N, De Tullio A, et al. Long-acting glucagon-like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: a retrospective cohort study. Andrology. 2024;12(3):633–642. doi: 10.1111/andr.13519 EDN: SNUMJY
  25. Demidova TY, Skuridina DV. The role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes mellitus. Russian Medical Journal. 2021;29(2):31–36. EDN: FCPYMN
  26. Zhang Y, Zhang K, Huang S, et al. Sarcopenia in type 2 diabetes mellitus. Medicine. 2024;103(16):e37666. doi: 10.1097/MD.0000000000037666 EDN: ESGJBY
  27. Saini K, Sharma S, Khan Y. DPP-4 inhibitors for treating T2DM. Front Mol Biosci. 2023;10:1130625. doi: 10.3389/fmob.2023.1130625 EDN: ALCFPW
  28. Zannad F, Cannon CP, Cushman WC, et al. Heart failure outcomes in type 2 diabetes taking alogliptin. Lancet. 2015;385(9982):2067–2076. doi: 10.1016/S0140-6736(14)62225-X EDN: VBMHSZ
  29. Singh LG, Ntelis S, Siddiqui T, et al. SGLT2 inhibitors continuation from outpatient to inpatient setting. Diabetes Care. 2024;47(6):933–940. doi: 10.2337/dc23-1129 EDN: NTCAHU
  30. Paik JM, Tesfaye H, Curhan GC, et al. SGLT2 inhibitors and nephrolithiasis risk. JAMA Intern Med. 2024;184(3):265–274. doi: 10.1001/jamainternmed.2023.7660 EDN: HQNQXG
  31. Wang J, Li X, Li Y, et al. SGLT2 inhibitors effects on bone metabolism. BMC Endocr Disord. 2024;24(1):52. doi: 10.1186/s12902-024-01575-8 EDN: PIBIPK
  32. Chitpim N, Leelahavarong P, Prawjaeng J, et al. Cost-utility of SGLT2 inhibitors in type 2 diabetes with CKD. Sci Rep. 2025;15(1):249. doi: 10.1038/s41598-024-81747-7 EDN: TBXMHG
  33. Fu EL, Mastrorilli J, Bykov K, et al. Hyperkalemia risk after initiating SGLT-2 inhibitors, GLP1 agonists or DPP-4 inhibitors in CKD and diabetes. Kidney Int. 2024;105(3):618–628. doi: 10.1016/j.kint.2023.11.025 EDN: FVNQRW
  34. Guo L, Wang J, Li L, et al. Safety of dapagliflozin plus metformin in Chinese type 2 diabetes patients. Diabetes Res Clin Pract. 2025;219:111959. doi: 10.1016/j.diabres.2024.111959 EDN: PDODWS
  35. Pozhilova EV, Novikov VE, Levchenkova OS. The mitochondrial ATP-dependent potassium channel and its pharmacological modulators. Reviews on Clinical Pharmacology and Drug Therapy. 2016;14(1):29–36. doi: 10.17816/RCF14129-36 EDN: VVEOFT
  36. Algorithms for Specialized Medical Care for Diabetes Patients. Dedov II, Shestakova MV, Mayorov AY. Eds. Moscow: Pechatnykh Del Master; 2023. 11. 231 p.
  37. Novikov VE, Levchenkova OS, Ivantsova EN. Possibilities of antihypoxant use for mitochondrial dysfunctions. Vestnik of the Smolensk State Medical Academy. 2020;19(1):41–55. EDN: TMVTOL
  38. Pozhilova EV, Novikov VE. Pharmacodynamics and clinical use of ACTH4-10 neuropeptide. Vestnik of the Smolensk State Medical Academy. 2020;19(3):76–86. doi: 10.37903/vsgma.2020.3.10 EDN: IUZEXY
  39. Novikov VE, Levchenkova OS, Pozhilova EV. Pharmacological preconditioning: opportunities and prospects. Vestnik of the Smolensk State Medical Academy. 2020;19(2):36–49. doi: 10.37903/vsgma.2020.2.6 EDN: OMTYRF
  40. Ponomareva NS, Novikov VE, Pozhilova EV. Prospects of pharmacological regulation of aquaporin function in CNS diseases. Reviews on Clinical Pharmacology and Drug Therapy. 2023;21(1):35–48. doi: 10.17816/RCF21135-48 EDN: UNKYAO
  41. Sychev DA, Tkacheva ON, Kotovskaya YV, et al. Pharmacotherapy in Elderly Patients. Moscow: CONGRESSKHIM; 2024. 124 p. (In Russ.) ISBN 978-5-6052709-2-8
  42. Koteshkova OM, Demidov NA, Antsiferov MB, et al. The use of combination drugs for the treatment of patients with type 2 diabetes. The Journal of General Medicine. 2020;(2):25–30. doi: 10.24411/2071-5315-2020-12208 EDN: DBHEHU
  43. Sorokina YA, Gavrilova DM, Kopylova MV, et al. Fixed combinations for sugar-decreasing preparations: application standards in the Russian federation, USA and Europe. International Research Journal. 2018;78(12):173–176. doi: 10.23670/IRJ.2018.78.12.031 EDN: ILXPWV
  44. Elderly Patient in General Practice: Physician’s Guide. Frolova EV, Kuznetsova OY, Eds. Moscow: GEOTAR-Media; 2023. 480 p. (In Russ.) ISBN: 978-5-9704-7566-9

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Eco-Vector, 2025

Creative Commons License
Este artigo é disponível sob a Licença Creative Commons Atribuição–NãoComercial–SemDerivações 4.0 Internacional.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 84654 от 01.02.2023 г.